We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,179.50 +12.00 (+0.23%) Dow Futures
38,314.00 +76.00 (+0.20%) Nasdaq Futures
18,226.25 +47.00 (+0.26%) Russell 2000 Futures
2,030.60 +10.80 (+0.53%) Crude Oil
85.38 -0.28 (-0.33%) Gold
2,369.60 -4.50 (-0.19%)
MacroGenics, Inc. (MGNX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 18.51 |
| Open | 18.38 |
| Bid | 17.53 x 200 |
| Ask | 17.59 x 300 |
| Day's Range | 17.12 - 18.54 |
| 52 Week Range | 4.29 - 21.88 |
| Volume | |
| Avg. Volume | 1,610,167 |
| Market Cap | 1.097B |
| Beta (5Y Monthly) | 2.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.15 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.78 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MGNX
Related Research
- MacroGenics, Inc.Daily – Vickers Top Buyers & Sellers for 10/05/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
GlobeNewswireMacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data, including safety and preliminary efficacy, by May 31Company plans to provide additional clinical data – including rPFS – in the Fall of 2024 ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing
Insider MonkeyMacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript March 7, 2024 MacroGenics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. We will begin the MacroGenics 2023 Fourth Quarter Corporate Progress and Financial Results Conference Call in just […]
Insider Monkey12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds. If you want to skip our discussion on the biotech industry, head over to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. Fitch Ratings maintains a Neutral outlook for the global pharmaceutical and biotech industry in […]
- Thomson Reuters StreetEvents
Q4 2023 MacroGenics Inc Earnings Call
Q4 2023 MacroGenics Inc Earnings Call
Motley FoolMacroGenics (MGNX) Q4 2023 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2023.
GuruFocus.comMacrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ...
Company's Cash Runway Extended into 2026 Amidst Clinical Progress
ZacksMacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -188.46% and 58.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADCPreclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACRConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical comp
GuruFocus.comInsider Sell: COO Eric Risser Sells 41,159 Shares of Macrogenics Inc (MGNX)
Eric Risser, the Chief Operating Officer of Macrogenics Inc (NASDAQ:MGNX), has sold 41,159 shares of the company on March 4, 2024, according to a recent SEC filing.
Simply Wall St.Are Investors Undervaluing MacroGenics, Inc. (NASDAQ:MGNX) By 48%?
Key Insights MacroGenics' estimated fair value is US$36.82 based on 2 Stage Free Cash Flow to Equity MacroGenics is...
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| XNCR Xencor, Inc. | |||
| KPTI Karyopharm Therapeutics Inc. | |||
| CTMX CytomX Therapeutics, Inc. | |||
| MRSN Mersana Therapeutics, Inc. | |||
| ATRA Atara Biotherapeutics, Inc. |
Similar to MGNX
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| CTMX CytomX Therapeutics, Inc. | |||
| NRIX Nurix Therapeutics, Inc. | |||
| KPTI Karyopharm Therapeutics Inc. | |||
| ELVN Enliven Therapeutics, Inc. | |||
| ARVN Arvinas, Inc. |
Analyst Price Targets (9)
Upgrades & Downgrades
| Upgrade | TD Cowen: Hold to Buy | 4/9/2024 | |
| Reiterates | JMP Securities: to Market Outperform | 4/4/2024 | |
| Maintains | Citigroup: Buy to Buy | 3/11/2024 | |
| Maintains | JMP Securities: Outperform to Outperform | 3/11/2024 | |
| Maintains | HC Wainwright & Co.: Neutral to Neutral | 3/11/2024 | |
| Maintains | BMO Capital: Outperform to Outperform | 3/8/2024 |
Company Profile
9704 Medical Center Drive
Rockville, MD 20850
United States
301 251 5172
https://www.macrogenics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 339
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
